Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: Role of NMDA vs. 5-HT1A receptors

Melanie A. Paquette, Alex A. Martinez, Teresa Macheda, Charles K. Meshul, Steven Johnson, S. Paul Berger, Andrea Giuffrida

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Amantadine and dextromethorphan suppress levodopa (L-DOPA)-induced dyskinesia (LID) in patients with Parkinson's disease (PD) and abnormal involuntary movements (AIMs) in the unilateral 6-hydroxydopamine (6-OHDA) rat model. These effects have been attributed to N-methyl-d-aspartate (NMDA) antagonism. However, amantadine and dextromethorphan are also thought to block serotonin (5-HT) uptake and cause 5-HT overflow, leading to stimulation of 5-HT1A receptors, which has been shown to reduce LID. We undertook a study in 6-OHDA rats to determine whether the anti-dyskinetic effects of these two compounds are mediated by NMDA antagonism and/or 5-HT1A agonism. In addition, we assessed the sensorimotor effects of these drugs using the Vibrissae-Stimulated Forelimb Placement and Cylinder tests. Our data show that the AIM-suppressing effect of amantadine was not affected by the 5-HT1A antagonist WAY-100635, but was partially reversed by the NMDA agonist d-cycloserine. Conversely, the AIM-suppressing effect of dextromethorphan was prevented by WAY-100635 but not by d-cycloserine. Neither amantadine nor dextromethorphan affected the therapeutic effects of L-DOPA in sensorimotor tests. We conclude that the anti-dyskinetic effect of amantadine is partially dependent on NMDA antagonism, while dextromethorphan suppresses AIMs via indirect 5-HT1A agonism. Combined with previous work from our group, our results support the investigation of 5-HT1A agonists as pharmacotherapies for LID in PD patients.

Original languageEnglish (US)
Pages (from-to)3224-3234
Number of pages11
JournalEuropean Journal of Neuroscience
Volume36
Issue number9
DOIs
StatePublished - Nov 2012

Fingerprint

Dextromethorphan
Amantadine
Receptor, Serotonin, 5-HT1A
Oxidopamine
Dyskinesias
Aspartic Acid
Parkinson Disease
Cycloserine
Serotonin
Levodopa
Serotonin 5-HT1 Receptor Antagonists
Serotonin 5-HT1 Receptor Agonists
Vibrissae
Forelimb
Therapeutic Uses

Keywords

  • 6-hydroxydopamine
  • Dyskinesia
  • L-DOPA
  • Parkinson's disease
  • Serotonin

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease : Role of NMDA vs. 5-HT1A receptors. / Paquette, Melanie A.; Martinez, Alex A.; Macheda, Teresa; Meshul, Charles K.; Johnson, Steven; Berger, S. Paul; Giuffrida, Andrea.

In: European Journal of Neuroscience, Vol. 36, No. 9, 11.2012, p. 3224-3234.

Research output: Contribution to journalArticle

Paquette, Melanie A. ; Martinez, Alex A. ; Macheda, Teresa ; Meshul, Charles K. ; Johnson, Steven ; Berger, S. Paul ; Giuffrida, Andrea. / Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease : Role of NMDA vs. 5-HT1A receptors. In: European Journal of Neuroscience. 2012 ; Vol. 36, No. 9. pp. 3224-3234.
@article{b6991f3d7bd34c77be2ed12c5c82ef05,
title = "Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: Role of NMDA vs. 5-HT1A receptors",
abstract = "Amantadine and dextromethorphan suppress levodopa (L-DOPA)-induced dyskinesia (LID) in patients with Parkinson's disease (PD) and abnormal involuntary movements (AIMs) in the unilateral 6-hydroxydopamine (6-OHDA) rat model. These effects have been attributed to N-methyl-d-aspartate (NMDA) antagonism. However, amantadine and dextromethorphan are also thought to block serotonin (5-HT) uptake and cause 5-HT overflow, leading to stimulation of 5-HT1A receptors, which has been shown to reduce LID. We undertook a study in 6-OHDA rats to determine whether the anti-dyskinetic effects of these two compounds are mediated by NMDA antagonism and/or 5-HT1A agonism. In addition, we assessed the sensorimotor effects of these drugs using the Vibrissae-Stimulated Forelimb Placement and Cylinder tests. Our data show that the AIM-suppressing effect of amantadine was not affected by the 5-HT1A antagonist WAY-100635, but was partially reversed by the NMDA agonist d-cycloserine. Conversely, the AIM-suppressing effect of dextromethorphan was prevented by WAY-100635 but not by d-cycloserine. Neither amantadine nor dextromethorphan affected the therapeutic effects of L-DOPA in sensorimotor tests. We conclude that the anti-dyskinetic effect of amantadine is partially dependent on NMDA antagonism, while dextromethorphan suppresses AIMs via indirect 5-HT1A agonism. Combined with previous work from our group, our results support the investigation of 5-HT1A agonists as pharmacotherapies for LID in PD patients.",
keywords = "6-hydroxydopamine, Dyskinesia, L-DOPA, Parkinson's disease, Serotonin",
author = "Paquette, {Melanie A.} and Martinez, {Alex A.} and Teresa Macheda and Meshul, {Charles K.} and Steven Johnson and Berger, {S. Paul} and Andrea Giuffrida",
year = "2012",
month = "11",
doi = "10.1111/j.1460-9568.2012.08243.x",
language = "English (US)",
volume = "36",
pages = "3224--3234",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease

T2 - Role of NMDA vs. 5-HT1A receptors

AU - Paquette, Melanie A.

AU - Martinez, Alex A.

AU - Macheda, Teresa

AU - Meshul, Charles K.

AU - Johnson, Steven

AU - Berger, S. Paul

AU - Giuffrida, Andrea

PY - 2012/11

Y1 - 2012/11

N2 - Amantadine and dextromethorphan suppress levodopa (L-DOPA)-induced dyskinesia (LID) in patients with Parkinson's disease (PD) and abnormal involuntary movements (AIMs) in the unilateral 6-hydroxydopamine (6-OHDA) rat model. These effects have been attributed to N-methyl-d-aspartate (NMDA) antagonism. However, amantadine and dextromethorphan are also thought to block serotonin (5-HT) uptake and cause 5-HT overflow, leading to stimulation of 5-HT1A receptors, which has been shown to reduce LID. We undertook a study in 6-OHDA rats to determine whether the anti-dyskinetic effects of these two compounds are mediated by NMDA antagonism and/or 5-HT1A agonism. In addition, we assessed the sensorimotor effects of these drugs using the Vibrissae-Stimulated Forelimb Placement and Cylinder tests. Our data show that the AIM-suppressing effect of amantadine was not affected by the 5-HT1A antagonist WAY-100635, but was partially reversed by the NMDA agonist d-cycloserine. Conversely, the AIM-suppressing effect of dextromethorphan was prevented by WAY-100635 but not by d-cycloserine. Neither amantadine nor dextromethorphan affected the therapeutic effects of L-DOPA in sensorimotor tests. We conclude that the anti-dyskinetic effect of amantadine is partially dependent on NMDA antagonism, while dextromethorphan suppresses AIMs via indirect 5-HT1A agonism. Combined with previous work from our group, our results support the investigation of 5-HT1A agonists as pharmacotherapies for LID in PD patients.

AB - Amantadine and dextromethorphan suppress levodopa (L-DOPA)-induced dyskinesia (LID) in patients with Parkinson's disease (PD) and abnormal involuntary movements (AIMs) in the unilateral 6-hydroxydopamine (6-OHDA) rat model. These effects have been attributed to N-methyl-d-aspartate (NMDA) antagonism. However, amantadine and dextromethorphan are also thought to block serotonin (5-HT) uptake and cause 5-HT overflow, leading to stimulation of 5-HT1A receptors, which has been shown to reduce LID. We undertook a study in 6-OHDA rats to determine whether the anti-dyskinetic effects of these two compounds are mediated by NMDA antagonism and/or 5-HT1A agonism. In addition, we assessed the sensorimotor effects of these drugs using the Vibrissae-Stimulated Forelimb Placement and Cylinder tests. Our data show that the AIM-suppressing effect of amantadine was not affected by the 5-HT1A antagonist WAY-100635, but was partially reversed by the NMDA agonist d-cycloserine. Conversely, the AIM-suppressing effect of dextromethorphan was prevented by WAY-100635 but not by d-cycloserine. Neither amantadine nor dextromethorphan affected the therapeutic effects of L-DOPA in sensorimotor tests. We conclude that the anti-dyskinetic effect of amantadine is partially dependent on NMDA antagonism, while dextromethorphan suppresses AIMs via indirect 5-HT1A agonism. Combined with previous work from our group, our results support the investigation of 5-HT1A agonists as pharmacotherapies for LID in PD patients.

KW - 6-hydroxydopamine

KW - Dyskinesia

KW - L-DOPA

KW - Parkinson's disease

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84868585089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868585089&partnerID=8YFLogxK

U2 - 10.1111/j.1460-9568.2012.08243.x

DO - 10.1111/j.1460-9568.2012.08243.x

M3 - Article

C2 - 22861201

AN - SCOPUS:84868585089

VL - 36

SP - 3224

EP - 3234

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 9

ER -